Castrate Resistant Prostate Cancer Enhertu Therapy

Recruiting now · Phase 2

Conditions studied: Prostate Cancer Metastatic, Prostate Cancer, CRPC

In brief

Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.

Key facts

Study ID

NCT06610825

Run by

Washington D.C. Veterans Affairs Medical Center

People needed

60

Starts

2025-03-05

Expected to finish

2028-10-01

Last updated by the study team

2026-04-13

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Pathologically confirmed adenocarcinoma of the prostate
• Diagnosis of mCRPC
• Documented progression on androgen deprivation and novel hormonal agents, with or without progression on taxane containing regimen
• Ongoing ADT to maintain serum testosterone levels below 50 ng/dL
• Formalin fixed paraffin embedded tumor tissue for HER2 immunohistochemistry
• Life expectancy 6 months
• ECOG 0 or 1
• LVEF at least 50%
• Adequate Blood Clotting function
• Adequate Organ and Bone Marrow function
• Adequate Renal function
• Adequate Hepatic function

You may not qualify if…

• History of interstitial lung disease or pneumonitis requiring steroids
• Significant coronary vascular disease
• Previous exposure to HER2 targeted therapy

Where it is running

• Washington DC VAMC — Washington D.C., District of Columbia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.